This Article Full Text Full Text (PDF) Data Supplement Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Skali, H. Articles by Solomon, S. D. Search for Related Content PubMed PubMed Citation Articles by Skali, H. Articles by Solomon, S. D. Pubmed/NCBI databases Medline Plus Health Information Heart Failure Related Collections Other heart failure Congestive AHA Statements and Guidelines

(Circulation. 2006;114:2298-2303.)
© 2006 American Heart Association, Inc.

Special Report

Variable Impact of Combining Fatal and Nonfatal End Points in Heart Failure Trials

Hicham Skali, MD, MSc; Marc A. Pfeffer, MD, PhD; Jacobus Lubsen, MD, PhD; Scott D. Solomon, MD

From Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass (H.S., M.A.P., S.D.S.); SOCAR Research SA, Nyon, Switzerland (J.L.); and Erasmus Medical Centre, Rotterdam, the Netherlands (J.L.).

Correspondence to Professor Marc A. Pfeffer, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail mpfeffer{at}rics.bwh.harvard.edu

Randomized clinical trials (RCTs) are a cornerstone of evidence-based medicine. Their design, implementation, and interpretation are sometimes subject to flaws and errors. To achieve statistical significance and economically feasible RCTs, the use of composite end points in heart failure (HF) trials has become more common. We analyzed the incremental value of combining HF hospitalizations with all-cause mortality in trials of chronic HF that enrolled >1000 placebo patients and had a mean follow-up >9 months. We tested the assumption that, compared with mortality, combining HF hospitalization with all-cause death would yield a consistently predictable increase in event rate across HF RCTs. Average placebo arm duration of follow-up was determined, and standardized placebo event rates per 100 patient-years were estimated. Twelve major HF RCTs were included in this analysis. There was a substantial relative increase in the event rate ranging from 64% to 134% when a composite end point was used. This increase was not related to disease severity as described by annual mortality rate. The relative contribution of combining HF hospitalization with all-cause mortality was, however, influenced by the duration of the trial. Combining HF hospitalization with all-cause mortality increases the overall event rate in HF clinical trials; the relative increase varies widely and is unrelated to disease severity. Longer-duration trials have a more predictable increase in events than short RCTs. Trial duration must be considered when composite end points are used during the design and interpretation of HF RCTs.

Key Words: heart failure • trials • methods

This article has been cited by other articles:

				A. J. Moss, W. J. Hall, D. S. Cannom, H. Klein, M. W. Brown, J. P. Daubert, N.A. M. Estes III, E. Foster, H. Greenberg, S. L. Higgins, et al. Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events N. Engl. J. Med., October 1, 2009; 361(14): 1329 - 1338. [Abstract] [Full Text] [PDF]

				C. E. Ventetuolo, R. L. Benza, A. J. Peacock, R. T. Zamanian, D. B. Badesch, and S. M. Kawut Surrogate and Combined End Points in Pulmonary Arterial Hypertension Proceedings of the ATS, July 15, 2008; 5(5): 617 - 622. [Abstract] [Full Text] [PDF]

				S. D. Solomon, J. Dobson, S. Pocock, H. Skali, J. J.V. McMurray, C. B. Granger, S. Yusuf, K. Swedberg, J. B. Young, E. L. Michelson, et al. Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure Circulation, September 25, 2007; 116(13): 1482 - 1487. [Abstract] [Full Text] [PDF]

				J. Wittes, E. Barrett-Connor, E. Braunwald, M. Chesney, H. J. Cohen, D. DeMets, L. Dunn, J. Dwyer, R. P. Heaney, V. Vogel, et al. Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board Clinical Trials, June 1, 2007; 4(3): 218 - 234. [Abstract] [PDF]